

Restoring Lives

Integra at a Glance

Today, the Company has more than \$1.5 billion in global revenue, with market-leading brands sold in 130 countries. Integra manufactures and sells medical technologies and products in two reportable business segments: Codman Specialty Surgical, also known as CSS, and Tissue Technologies.

We have an advanced position in the medical device industry as a result of:

- Achieving no. 1 or 2 position in attractive markets
- Depth and breadth of portfolio and technologies
- Tenured, trusted salesforce and channels
- Global footprint for technology access and commercialization
- Strong balance sheet and financial discipline
- Systematic M&A aimed at accretive growth segments

1989

Founded

3,946

Colleagues

~90%


Recurring/
Consumables




REVENUE FY2023

\$1.54B

BY PRODUCT CATEGORY



BY GEOGRAPHY



1989

Founded

3,946

Colleagues

~90%

Recurring/
Consumables

14

Manufacturing Sites

3

Primary Global
Third-Party Logistics
Distribution Centers

130

Countries Served

220+

Distributor Partners

Our Business Segments


Codman Specialty Surgical

Codman Specialty Surgical consists of market-leading technologies and instrumentation for a wide range of specialties, such as neurosurgery, neurocritical care, otolaryngology and otorhinolaryngology. Integra is the world leader in neurosurgery med tech, and our global scale allows us to offer solutions across multiple disease states like brain lesion surgery, including minimally invasive techniques; traumatic brain injury care and neuromonitoring; and hydrocephalus care. We are also one of the top three providers of instruments used in precision, specialty and general surgical, and now also ENT procedures from recently acquired Acclarent, Inc.



REVENUE FY2023

\$1.0B



LEADING BRANDS

| | |
|--------------|--------------|
| MAYFIELD | ISOCOOL® |
| CUSA® | Integra® DUO |
| Certas® Plus | TruDi® |
| Bactiseal® | AERA® |
| ICP Express® | |

New Product Innovation

\$18.9M

Revenue

+62%

Increase from 2022


Tissue Technologies

The Tissue Technologies segment focuses on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. This segment of our business represents the broadest set of regenerative technology platforms in the industry, ranging from highly engineered collagen technologies to bovine dermis, porcine and amniotic tissue, and bioabsorbable matrix.



REVENUE FY2023

\$0.5B



LEADING BRANDS

| | |
|--------------------------|--------------|
| Integra® Dermal Matrices | MicroMatrix® |
| Gentrix® | SurgiMend® |
| DuraSorb® | MediHoney® |
| PriMatrix® | |

New Product Innovation

\$2.1M

Revenue

+175%

Increase from 2022

Integrated Growth Strategy

In 2023, Integra maintained its focus on the five pillars of our integrated growth strategy established in 2022. These pillars are comprised of three growth drivers—levers that directly impact the Company's growth ambitions—and two enablers that make integrated growth possible. This approach continues to enable us to strengthen operational capacity and efficiency and accelerate innovation and growth, and in 2023 led to key accomplishments in each of the pillars.

DRIVING AN INTEGRATED GROWTH STRATEGY

Strengthening Operational Capability and Efficiency, Accelerating Innovation and Growth

GROWTH DRIVERS

Innovate for Outcomes



Grow International



Broaden Impact on Care Pathways



2023 ACCOMPLISHMENTS

Relaunched CereLink® in international markets; submitted 510(k) for CereLink in the U.S.

Submitted clinical PMA amendment for SurgiMend

Completed enrollment in DuraSorb® PMA trial

Obtained 510(k) for next generation Aurora® Surgiscope

Opened regenerative technology innovation and learning center in Plainsboro, New Jersey

High single-digit growth in international markets

Double-digit growth in China

International portfolio expansion of DuraGen®, CUSA and 100+ product registrations

Realignment of international organization, building local commercial capabilities

Buildout of In-China-for-China (ICFC) manufacturing capability

Signed definitive agreement to acquire the Acclarent® ENT business

Successful commercial and clinical integration of SIA acquisition

Double-digit growth in UBM platform

Finalized market research and design for digital innovation pilots

ENABLERS

Drive Operations and Customer Excellence



Cultivate a High-Performance Culture



Expanded Le Locle, Switzerland site, enabling launch of differentiated NPIs

Established ICFC manufacturing capacity, ready for 2024 validation

Strengthened plant management and quality leadership

Invested in manufacturing capacity and resilience

Enhanced procurement category management

Deepened plant level KPI measurement

Awarded Great Place to Work in China


Formed UNIDOS employee resource group

Further strengthened executive leadership team with key hires and capabilities

2023 Highlights

Environmental

2023 SCOPE 1, 2 AND 3



Improved GHG emission data collection through process improvement, which allowed us to calculate our emissions with fuel and electricity usage compared to spend data in 2021

Conducted energy reduction assessments to identify opportunities that can be applied to worldwide operations

~32,000

Devices were Maintained through our Service and Repair Facilities

Social

7M+

Patients Touched

\$4.63M


In Products Donated

\$417K+

In Grant Donations by the Integra Foundation to **67 nonprofits**



COLLEAGUES BY GENDER



Governance

100%

Of Employees Completed Code of Conduct and Anti-Bribery and -Corruption Training

100%

Of New Hires Completed Unconscious Bias Training


33%

Of Our Board Members are Women

22%

Of Our Board Members are from Ethnically Diverse Backgrounds

BOARD DIVERSITY



Opened a **new research and development facility** dedicated to pioneering new advances in treatment pathways



INTEGRA LIFESCIENCES

1100 Campus Road, Princeton, New Jersey 08540

WWW.INTEGRALIFE.COM/ESG-REPORT

INTEGRA 